Drug Profile
Inebilizumab - Horizon Therapeutics plc
Alternative Names: 16C4-aFuc; A-fucosylated anti-CD19 antibody; Anti-CD19 MAb-Horizon Therapeutics plc; Inebilizumab-cdon; MEDI 551; MT-0551; UPLIZNA; VIB-0551Latest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator Duke University
- Developer Horizon Therapeutics plc; Jiangsu Hansoh Pharmaceutical; MedImmune; Mitsubishi Tanabe Pharma Corporation
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Neuromyelitis optica
- Phase III Autoimmune disorders; Myasthenia gravis; Systemic scleroderma
- No development reported Renal transplant rejection
- Discontinued B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Multiple myeloma; Multiple sclerosis
Most Recent Events
- 06 Feb 2024 Horizon Therapeutics completes enrolment in its phase III trial in Autoimmune disorders in Germany, Hungary, Japan, Poland, Sweden, Ukraine, the US, Argentina, Australia, Canada, China, France, Hong Kong, India, Ireland, Israel, Italy, Mexico, Netherlands, Spain, Turkey and the UK (NCT04540497)
- 31 Jan 2024 Horizon Therapeutics completes enrolment in its phase III clinical trials in Myasthenia gravis in USA, Argentina, Brazil, Belarus, Canada, China, Denmark, France, Germany, Italy, Poland, India, Russia, Spain, South Korea, Taiwan, Turkey, Ukraine (IV) (NCT04524273)
- 15 Dec 2023 Registered for Neuromyelitis optica in Canada (IV)